AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma
AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma
复制标题
DOI：
10.1182/blood-2015-01-623900
复制
发表时间：
2015-07-09
期刊：
影响因子：
20.3
通讯作者：
Kaplan, Lawrence
中科院分区：
文献类型：
--
作者：
Noy, Ariela;Lee, Jeannette Y.;Kaplan, Lawrence
用于Burkitt淋巴瘤的剂量密集方案的毒性促使对HIV阳性患者的环磷酰胺、长春新碱、多柔比星、高剂量甲氨蝶呤/异环磷酰胺、依托泊苷和高剂量阿糖胞苷（CODOX-M/IVAC）进行修改。我们增加利妥昔单抗，减少和/或重新安排环磷酰胺和甲氨蝶呤，长春新碱封顶，并使用联合鞘内化疗。抗生素预防和生长因子的支持是必要的;高活性抗逆转录病毒治疗（HAART）是自由裁量权。从2007年到2010年，13个艾滋病联盟中心招募了34名患者。中位年龄为42岁（范围，19-55岁），34名患者中有32名为高风险，74%患有III至IV期BL，CD 4计数为195个细胞/μ L（范围，0-721个细胞/μ L），5名患者（15%）CD 4
The toxicity of dose-intensive regimens used for Burkitt lymphoma prompted modification of cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for HIV-positive patients. We added rituximab, reduced and/or rescheduled cyclophosphamide and methotrexate, capped vincristine, and used combination intrathecal chemotherapy. Antibiotic prophylaxis and growth factor support were required; highly active antiretroviral therapy (HAART) was discretionary. Thirteen AIDS Malignancy Consortium centers enrolled 34 patients from 2007 to 2010. Median age was 42 years (range, 19-55 years), 32 of 34 patients were high risk, 74% had stage III to IV BL and CD4 count of 195 cells per mu L (range, 0-721 cells per mu L), and 5 patients (15%) had CD4